(Q41055102)

26 September 2017

1 reference

title

Treatment and prognostic factors in acute myeloid leukaemia (English)

1 reference

26 September 2017

1 reference

2

Liesveld JL

1 reference

26 September 2017

Rowe JM

1

1 reference

26 September 2017

publication date

1 March 1996

1 reference

Best Practice and Research: Clinical Haematology

26 September 2017

published in

1 reference

26 September 2017

volume

9

1 reference

26 September 2017

issue

1

1 reference

26 September 2017

page(s)

87-105

1 reference

Long term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Gene-marking to trace origin of relapse after autologous bone-marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Autologous bone marrow transplant in acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Double intensive consolidation chemotherapy in adult acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Etoposide in acute leukemia. Past experience and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Does in vitro bone marrow purging improve the outcome after autologous bone marrow transplantation?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Interleukin 2 treatment in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Effect of Granulocyte Colony-Stimulating Factor after Intensive Induction Therapy in Relapsed or Refractory Acute Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

The predictive value of in-vitro techniques in acute non-lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980038-2

7 January 2021

10.1016/S0950-3536(96)80038-2

Identifiers

DOI

1 reference

26 September 2017

1 reference